StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.20−0.10 (-4.35%)

Close on Nov 16, 2026Market cap $105.05MP/E –Yield –

Minerva Neurosciences r&d expenses

Research and development expenses are spending on new products and technology.

Minerva Neurosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.54M, up 137.9% year over year. For fiscal 2025 it was $5.76M, down 51.6% from the year before. Over ten years it grew -11.0% a year on average. The highest annual figure on record is $58.12M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.76M-51.6%
FY2024Dec 31, 2024$11.90M-6.3%
FY2023Dec 31, 2023$12.71M-13.3%
FY2022Dec 31, 2022$14.65M-54.3%
FY2021Dec 31, 2021$32.04M+45.4%
FY2020Dec 31, 2020$22.04M-62.1%
FY2019Dec 31, 2019$58.12M+66.6%
FY2018Dec 31, 2018$34.89M+15.3%
FY2017Dec 31, 2017$30.26M+48.0%
FY2016Dec 31, 2016$20.44M+10.3%
FY2015Dec 31, 2015$18.53M-56.8%
FY2014Dec 31, 2014$42.91M+5956.3%
FY2013Dec 31, 2013$708.49K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.19M+453.7%
Q1 FY2026Mar 31, 2026$5.25M+285.7%
Q4 FY2025Dec 31, 2025$2.17M+9.6%
Q3 FY2025Sep 30, 2025$925.38K-51.0%
Q2 FY2025Jun 30, 2025$1.30M-66.4%
Q1 FY2025Mar 31, 2025$1.36M-67.3%
Q4 FY2024Dec 31, 2024$1.98M-58.0%
Q3 FY2024Sep 30, 2024$1.89M-45.2%
Q2 FY2024Jun 30, 2024$3.86M+104.5%
Q1 FY2024Mar 31, 2024$4.17M+57.0%
Q4 FY2023Dec 31, 2023$4.72M+48.0%
Q3 FY2023Sep 30, 2023$3.44M+45.5%
Q2 FY2023Jun 30, 2023$1.89M-54.3%
Q1 FY2023Mar 31, 2023$2.65M-46.5%
Q4 FY2022Dec 31, 2022$3.19M-83.0%
Q3 FY2022Sep 30, 2022$2.37M-47.5%
Q2 FY2022Jun 30, 2022$4.13M-25.2%
Q1 FY2022Mar 31, 2022$4.96M+52.2%
Q4 FY2021Dec 31, 2021$18.75M+427.9%
Q3 FY2021Sep 30, 2021$4.51M-2.7%
Q2 FY2021Jun 30, 2021$5.52M-4.3%
Q1 FY2021Mar 31, 2021$3.26M-59.7%
Q4 FY2020Dec 31, 2020$3.55M-87.5%
Q3 FY2020Sep 30, 2020$4.64M-52.1%
Q2 FY2020Jun 30, 2020$5.77M-30.7%
Q1 FY2020Mar 31, 2020$8.08M-30.4%
Q4 FY2019Dec 31, 2019$28.52M+216.7%
Q3 FY2019Sep 30, 2019$9.67M+15.6%
Q2 FY2019Jun 30, 2019$8.32M-8.2%
Q1 FY2019Mar 31, 2019$11.61M+37.4%
Q4 FY2018Dec 31, 2018$9.01M+37.7%
Q3 FY2018Sep 30, 2018$8.37M-6.6%
Q2 FY2018Jun 30, 2018$9.06M+26.8%
Q1 FY2018Mar 31, 2018$8.45M+11.0%
Q4 FY2017Dec 31, 2017$6.54M+0.7%
Q3 FY2017Sep 30, 2017$8.96M+53.0%
Q2 FY2017Jun 30, 2017$7.14M–
Q1 FY2017Mar 31, 2017$7.61M–
Q4 FY2016Dec 31, 2016$6.50M–
Q3 FY2016Sep 30, 2016$5.85M–

More Minerva Neurosciences figures

See a number that looks wrong?